Claims

[Claim 1]

~~An antitumor composition comprising the following~~Use of compound (B) or a salt thereof in the manufacture of a pharmaceutical composition for the prevention or treatment of a tumor, wherein the pharmaceutical composition is to be administered ~~for use~~ in combination with ~~the following~~an antitumor agent (A~~):~~), wherein

the antitumor agent (A) comprises at least one antitumor agent selected from the group consisting of alkylating agents, CD20 recognition molecules, DNA methylation inhibitors, pyrimidine antimetabolites, purine antimetabolites, antifolates, Bcl-2 inhibitors, and tyrosine kinase inhibitors~~;~~, and

~~(B) a~~ the compound ~~or a salt thereof~~(B) is represented by the following formula (1):



(I)

wherein

R^1 represents a halogen atom~~, an aryl group, an aryloxy group,~~ or a ~~lower~~C1-6 alkyl group optionally substituted with one or more halogen atoms;

R^2 represents a hydrogen atom or~~, a halogen atom,~~ a ~~lower~~C1-6 alkyl group~~, or a lower alkoxy group~~; and

m represents an integer of 1 to 2~~3~~, provided that when m represents 2~~ or 3~~, R^1 is the same or different.

[Claim 2]

~~An antitumor composition comprising the following~~Use of compound (B) or a salt thereof in the manufacture of a pharmaceutical composition for the prevention or treatment of a tumor, wherein the pharmaceutical composition is to be administered ~~use in administration~~ to a person who will receive or has received ~~the following~~an antitumor agent (A), wherein

one of the pharmaceutical composition and the antitumor agent (A) is to be administered several minutes to several tens of minutes or 1 to 12 hours after completion of the administration of the other~~:~~,

the antitumor agent (A) comprises at least one antitumor agent selected from the group consisting of alkylating agents, CD20 recognition molecules, DNA methylation inhibitors, pyrimidine antimetabolites, purine antimetabolites, antifolates, Bcl-2 inhibitors, and tyrosine kinase inhibitors~~;~~, and

the compound (B) ~~a compound or a salt thereof~~is represented by the following formula (1):



(I)

wherein

R^1 represents a halogen atom~~, an aryl group, an aryloxy group,~~ or a ~~lower~~C1-6 alkyl group optionally substituted with one or more halogen atoms;

R^2 represents a hydrogen atom or~~, a halogen atom,~~ a ~~lower~~C1-6 alkyl group~~, or a lower alkoxy group~~; and

m represents an integer of 1 to 2~~3~~, provided that when m represents 2~~ or 3~~, R^1 is the same or different.

[Claim 3]

An antitumor composition comprising:

~~the following~~an antitumor agent (A~~), ~~); and

~~the following~~a compound (B) or a salt thereof~~:~~, wherein

the antitumor agent (A) comprises at least one antitumor agent selected from the group consisting of alkylating agents, CD20 recognition molecules, DNA methylation inhibitors, pyrimidine antimetabolites, purine antimetabolites, antifolates, Bcl-2 inhibitors, and tyrosine kinase inhibitors~~;~~, and

the compound (B) ~~a compound or a salt thereof~~is represented by the following formula (1):



(I)

wherein

R^1 represents a halogen atom~~, an aryl group, an aryloxy group,~~ or a ~~lower~~C1-6 alkyl group optionally substituted with one or more halogen atoms;

R^2 represents a hydrogen atom or~~, a halogen atom,~~ a ~~lower~~C1-6 alkyl group~~, or a lower alkoxy group~~; and

m represents an integer of 1 to 2~~3~~, provided that when m represents 2~~ or 3~~, R^1 is the same or different.

[Claim 4]

The composition according to ~~any one of~~ claim~~s~~ 1 or 2~~to 3~~, wherein the compound (B) or ~~a~~ the salt thereof is at least one compound or a salt thereof selected from the group consisting of:

~~N-{6-[2-fluoro-4-(methylamino)phenoxy]pyridin-3-yl}-4-phenoxybenzamide,~~
~~N-{6-[2-fluoro-4-(methylamino)phenoxy]pyridin-3-yl}biphenyl-4-carboxamide,~~
~~N-{6-[2-fluoro-4-(methylamino)phenoxy]pyridin-3-yl}-4-(trifluoromethyl)benzamide,~~
~~2-fluoro-N-{6-[2-fluoro-4-(methylamino)phenoxy]pyridin-3-yl}-4-(trifluoromethyl)benzamide,~~
~~2,3,4-trifluoro-N-{6-[2-fluoro-4-(methylamino)phenoxy]pyridin-3-yl}-benzamide,~~
~~N-{6-[2-methyl-4-(methylamino)phenoxy]pyridin-3-yl}-4-phenoxybenzamide,~~
~~N-{6-[2-methyl-4-(methylamino)phenoxy]pyridin-3-yl}biphenyl-4-carboxamide,~~
N-{6-[2-methyl-4-(methylamino)phenoxy]pyridin-3-yl}-4-(trifluoromethyl)benzamide,
2-fluoro-N-{6-[2-methyl-4-(methylamino)phenoxy]pyridin-3-yl}-4-(trifluoromethyl)benzamide,
~~N-{6-[4-(methylamino)phenoxy]pyridin-3-yl}-4-phenoxybenzamide,~~
~~N-{6-[4-(methylamino)phenoxy]pyridin-3-yl}biphenyl-4-carboxamide,~~
~~N-{6-[2-methoxy-4-(methylamino)phenoxy]pyridin-3-yl}-4-(trifluoromethyl)benzamide,~~
~~N-{6-[2-methoxy-4-(methylamino)phenoxy]pyridin-3-yl}-4-phenoxybenzamide,~~
~~N-{6-[2-methoxy-4-(methylamino)phenoxy]pyridin-3-yl}biphenyl-4-carboxamide,~~
~~2-fluoro-N-{6-[2-methoxy-4-(methylamino)phenoxy]pyridin-3-yl}-4-(trifluoromethyl)benzamide,~~
~~2,3,4-trifluoro-N-{6-[2-methoxy-4-(methylamino)phenoxy]pyridin-3-yl}benzamide,~~
~~2,3,4-trifluoro-N-{6-[2-methyl-4-(methylamino)phenoxy]pyridin-3-yl}benzamide,~~
N-{6-[4-(methylamino)phenoxy]pyridin-3-yl}-4-(trifluoromethyl)benzamide, and
2-fluoro-N-{6-[4-(methylamino)phenoxy]pyridin-3-yl}-4-(trifluoromethyl)benzamide~~, and~~
~~2,3,4-trifluoro-N-{6-[4-(methylamino)phenoxy]pyridin-3-yl}benzamide~~.

[Claim 5]

The composition according to claim 3, wherein the compound (B) or ~~a~~the salt thereof is at least one compound or a salt thereof selected from the group consisting of:
N-{6-[2-methyl-4-(methylamino)phenoxy]pyridin-3-yl}-4-(trifluoromethyl)benzamide,
2-fluoro-N-{6-[2-methyl-4-(methylamino)phenoxy]pyridin-3-yl}-4-(trifluoromethyl)benzamide,
N-{6-[4-(methylamino)phenoxy]pyridin-3-yl}-4-(trifluoromethyl)benzamide, and
2-fluoro-N-{6-[4-(methylamino)phenoxy]pyridin-3-yl}-4-(trifluoromethyl)benzamide.

[Claim 6~~5~~]

A kit comprising:
~~the following~~an antitumor agent (A~~), ~~);~~ and
an antitumor composition comprising ~~the following~~a compound (B) or a salt thereof~~:~~, wherein the antitumor agent (A) comprises at least one antitumor agent selected from the group consisting of alkylating agents, CD20 recognition molecules, DNA methylation inhibitors, pyrimidine antimetabolites, purine antimetabolites, antifolates, Bcl-2 inhibitors, and tyrosine kinase inhibitors~~;~~, and

the compound (B) ~~a compound or a salt thereof~~is represented by the following formula (1):



(I)

wherein

R^1 represents a halogen atom~~, an aryl group, an aryloxy group,~~ or a ~~lower~~C1-6 alkyl group optionally substituted with one or more halogen atoms;

R^2 represents a hydrogen atom or~~, a halogen atom,~~ a ~~lower~~C1-6 alkyl group~~, or a lower alkoxy group~~; and

m represents an integer of 1 to 2~~3~~, provided that when m represents 2~~ or 3~~, R^1 is the same or different.

~~[Claim 6]~~

~~A method for preventing or treating a tumor, the method comprising administering the following antitumor agent (A) and the following compound (B) or a salt thereof to a subject:~~

~~(A) at least one antitumor agent selected from the group consisting of alkylating agents, CD20 recognition molecules, DNA methylation inhibitors, pyrimidine antimetabolites, purine antimetabolites, antifolates, Bcl-2 inhibitors, and tyrosine kinase inhibitors;~~

~~(B) a compound or a salt thereof represented by the following formula (1):~~



~~(I)~~

~~wherein~~

~~R^1 represents a halogen atom, an aryl group, an aryloxy group, or a lower alkyl group optionally substituted with one or more halogen atoms;~~

~~R^2 represents a hydrogen atom, a halogen atom, a lower alkyl group, or a lower alkoxy group; and~~

~~m represents an integer of 1 to 3, provided that when m represents 2 or 3, R^1 is the same or different.~~

[Claim 7]

~~The following~~Use of ~~compound (B) or a salt thereof~~ an antitumor agent (A) in the manufacture of a pharmaceutical composition for ~~use in combination with the following antitumor agent (A) in~~ the prevention or treatment of a tumor~~:~~, wherein

the antitumor agent (A) comprises at least one antitumor agent selected from the group consisting of alkylating agents, CD20 recognition molecules, DNA methylation inhibitors,

pyrimidine antimetabolites, purine antimetabolites, antifolates, Bcl-2 inhibitors, and tyrosine kinase inhibitors~~;~~, and the pharmaceutical composition is to be administered in combination with a compound (B) or a salt thereof, wherein

the compound (B) ~~a compound or a salt thereof~~is represented by the following formula (1):



(I)

wherein

R^1 represents a halogen atom~~, an aryl group, an aryloxy group,~~ or a ~~lower~~C1-6 alkyl group optionally substituted with one or more halogen atoms;

R^2 represents a hydrogen atom or~~, a halogen atom,~~ a ~~lower~~C1-6 alkyl group~~, or a lower alkoxy group~~; and

m represents an integer of 1 to 2~~3~~, provided that when m represents 2~~ or 3~~, R^1 is the same or different.